|Bid||5.00 x 4000|
|Ask||5.05 x 800|
|Day's range||5.00 - 5.15|
|52-week range||4.70 - 20.05|
|PE ratio (TTM)||N/A|
|Earnings date||7 Nov 2017 - 13 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||12.33|
On a per-share basis, the South San Francisco, California-based company said it had a loss of 37 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.
Calithera Biosciences' (CALA) lead pipeline candidate, CB-839, gets fast track status in the United States for the treatment of kidney cancer.
Calithera Biosciences Inc. shares surged 15% in premarket trade Wednesday, after the company said it has won fast track designation from the U.S. Food and Drug Administration for a treatment for renal ...
Deerfield Management is placing a bet on the emerging immuno-metabolism field by committing $36 million to startup Dracen Pharmaceuticals Inc.
On a per-share basis, the South San Francisco, California-based company said it had a loss of 31 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed ...
Calithera Biosciences (CALA) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics
With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.
The South San Francisco, California-based company said it had a loss of 17 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics
Calithera Biosciences (CALA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.
Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences